Cosomil
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cosomil - overview
Established
2022
Location
Tokyo, -, Japan
Primary Industry
Biotechnology
About
Based in Tokyo, Japan, and founded in 2022, Cosomil, Inc. d. b. a Cosomil operates as a biotechnology company that performs research and develops liquid biopsy technologies.
The company was Co-founded by Kagamiyu (CEO), Sakamoto Shingo (CTO), Toru Komatsu, and Rikiya Watanabe. In February 2026, Cosomil raised an undisclosed amount in series A funding led by Delight Ventures with participation from other investors Animal Spirits, Gogin Capital, ANRI and GREEN CORE. The company develops testing technology for medical treatments. It develops liquid biopsy technologies that can assist in the early detection of cancers and other illnesses.
The firm develops healthcare solutions using fluorescent enzyme substrates and microdevices. The company plans to use the February 2026 funding to accelerate the R&D and practical deployment of its single‑molecule liquid biopsy–based cancer screening tests in Japan and the United States.
Current Investors
ANRI, Coral Capital, GREEN CORE
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.cosomil.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.